A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease
A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85724, United States
New Haven, Connecticut 06510, United States
Indianapolis, Indiana 46202, United States
Kansas City, Kansas 66160, United States
Pittsburgh, Pennsylvania 15213, United States
Greenville, South Carolina 29615, United States
Bennington, Vermont 05201, United States
Vancouver, British Columbia V6T 2B5, Canada